Literature DB >> 12384362

An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus.

Franziska Schaaff1, Andrea Reipert, Gabriele Bierbaum.   

Abstract

The emergence of intermediate vancomycin resistance, mainly in methicillin-resistant Staphylococcus aureus strains, has become a great concern. Thorough characterization of clinical and laboratory vancomycin-intermediately resistant S. aureus (VISA) strains identified multiple, resistance-associated changes most probably due to stepwise mutations. We hypothesized that an elevated mutation frequency as found, e.g., in mutator strains defective in DNA mismatch repair could allow rapid acquisition of adaptive mutations in the presence of vancomycin. We therefore subjected S. aureus RN4220 and its isogenic mutator strain, the mutS-knockout mutant RN4220DeltamutS, to a stepwise vancomycin selection procedure. Vancomycin resistance evolved much more quickly in the mutator background than in the wild type (5 versus 19 passages, respectively). In addition, a higher resistance level could be reached (MIC, 32 versus 4 micro g/ml, respectively). The susceptibility to other antibiotics with the exception of teicoplanin remained unchanged. Concomitantly with increasing vancomycin resistance, a loss of phage typeability and differences in growth behavior as well as an improved ability to regrow at high vancomycin concentrations were observed. In conclusion, an elevated mutation rate in S. aureus led to the rapid development of vancomycin resistance, indicating that a high mutation frequency could be one of the factors that favor the emergence of vancomycin resistance in S. aureus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384362      PMCID: PMC128741          DOI: 10.1128/AAC.46.11.3540-3548.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Rapid field inversion gel electrophoresis in combination with an rRNA gene probe in the epidemiological evaluation of staphylococci.

Authors:  R V Goering; T D Duensing
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.

Authors:  H Hanaki; H Labischinski; Y Inaba; N Kondo; H Murakami; K Hiramatsu
Journal:  J Antimicrob Chemother       Date:  1998-09       Impact factor: 5.790

3.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

4.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

5.  The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage.

Authors:  B N Kreiswirth; S Löfdahl; M J Betley; M O'Reilly; P M Schlievert; M S Bergdoll; R P Novick
Journal:  Nature       Date:  1983 Oct 20-26       Impact factor: 49.962

6.  Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus.

Authors:  K Sieradzki; M G Pinho; A Tomasz
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

7.  Sigma(B) activity depends on RsbU in Staphylococcus aureus.

Authors:  P Giachino; S Engelmann; M Bischoff
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

8.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

9.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

10.  Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity.

Authors:  O P Kuipers; M M Beerthuyzen; R J Siezen; W M De Vos
Journal:  Eur J Biochem       Date:  1993-08-15
View more
  30 in total

1.  Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus.

Authors:  Alexander J O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains.

Authors:  Arunachalam Muthaiyan; Radheshyam K Jayaswal; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil.

Authors:  I C V Palazzo; M L C Araujo; A L C Darini
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

5.  Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.

Authors:  Hiep N'Guyen Trong; Anne-Laure Prunier; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

6.  DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Jian-Qi Lian; Hui-Min Neoh; Ethel Reyes; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Experimental adaptation of Salmonella typhimurium to mice.

Authors:  Annika I Nilsson; Elisabeth Kugelberg; Otto G Berg; Dan I Andersson
Journal:  Genetics       Date:  2004-11       Impact factor: 4.562

8.  Mutations in the DNA mismatch repair proteins MutS and MutL of oxazolidinone-resistant or -susceptible Enterococcus faecium.

Authors:  Rob J Willems; Janetta Top; Derek J Smith; David I Roper; Sarah E North; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 9.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

Review 10.  Genome dynamics in major bacterial pathogens.

Authors:  Ole Herman Ambur; Tonje Davidsen; Stephan A Frye; Seetha V Balasingham; Karin Lagesen; Torbjørn Rognes; Tone Tønjum
Journal:  FEMS Microbiol Rev       Date:  2009-05       Impact factor: 16.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.